They are funded through until at least mid next year by which time they will have results of three phase 2 trials. The most important milestone this year is the interim data release for SNT 5505 in myelofibrosis - and a presentation at ASH in December. Spec buy and hold until then in my opinion.
They are funded through until at least mid next year by which...
Add SNT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
1.7¢ |
Change
0.001(6.25%) |
Mkt cap ! $20.29M | |||
| Open | High | Low | Value | Volume |
| 1.6¢ | 1.7¢ | 1.6¢ | $1.248K | 76.43K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 1214731 | 1.6¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 1.7¢ | 876421 | 8 |
View Market Depth
| Last trade - 16.10pm 01/05/2024 (20 minute delay) ? |
|
|||||
|
Last
1.7¢ |
Change
0.001 ( 6.25 %) |
||||
| Open | High | Low | Volume | ||
| 1.7¢ | 1.7¢ | 1.7¢ | 24111 | ||
| Last updated 15.59pm 01/05/2024 ? | |||||
| SNT (ASX) Chart |